Get weekly updates on this stock
VR This creator notes Vertex Pharmaceuticals' joint FDA approval with CRISPR Therapeutics for Casgevy, a gene-editing therapy for sickle cell disease.…
This creator notes Vertex Pharmaceuticals' joint FDA approval with CRISPR Therapeutics for Casgevy, a gene-editing therapy for sickle cell disease. They view this as a groundbreaking development in gene editing, suggesting future growth potential as the technology expands to treat more widespread conditions.
This creator notes Vertex Pharmaceuticals' joint FDA approval with CRISPR Therapeutics for Casgevy, a gene-editing therapy for sickle cell disease. They view this as a groundbreaking development in gene editing, suggesting future growth potential as the technology expands to treat more widespread conditions.
“the first ever Gene editing approval was uh given to crisper Therapeutics and vertex Pharmaceuticals for a uh medicine called kevi”
Cathie Wood highlights Vertex as a company utilizing gene editing to develop cures for chronic diseases such as diabetes. She believes that advancements in gene editing, combined with DNA sequencing and AI, hold the promise of outright cures, addressing significant healthcare costs.
“We're seeing companies like Crispr Therapeutics and Vertex working with gene editing to cure diabetes which is from a chronic set of conditions one of the biggest budget busters of all.”
The YouTuber recommends Vertex Pharmaceuticals due to its strong pipeline, expanding beyond cystic fibrosis, and its valuation at 16 times earnings and 7 times sales, which is 47% below its five-year average. The company also boasts a strong balance sheet with significant cash reserves, providing stability through potential pipeline gaps.
The YouTuber recommends Vertex Pharmaceuticals due to its strong pipeline, expanding beyond cystic fibrosis, and its valuation at 16 times earnings and 7 times sales, which is 47% below its five-year average. The company also boasts a strong balance sheet with significant cash reserves, providing stability through potential pipeline gaps.
“shares a vertex trade for just 16 times earnings and seven times on a price to sales basis and that sales multiple is 47 below the five-year average of 14 times sales so so definitely in that value stock territory”
Vertex Pharmaceuticals is added to the 'super ETF' as a unique holding from the ARK Genomic Revolution ETF, which focuses on companies innovating in biotech and healthcare technology.
“from here i'll add exact sciences ticker exas pacific biosciences ticker pacb and vertex pharmaceuticals ticker vrtx”
A named stock, a clear buy or sell stance, and real reasoning. Passing mentions and hype are filtered out.
Each channel counts once per stock, so a single loud voice can't skew the ranking.
We weigh how many creators agree, how convinced they are, and how recent each call is.
2 finance YouTubers analysed Vertex Pharmaceuticals with qualified reasoning — consensus: Buy, average analysis quality 75/100. This is not financial advice; review the individual analyses and sources above.
Among the channels covering Vertex Pharmaceuticals, 2 are buying and 0 are selling or avoiding — overall Buy.
The price targets mentioned for Vertex Pharmaceuticals range 258. Targets are the YouTubers' own; not a guarantee.
Only qualified analyses count: a clear buy/sell stance on Vertex Pharmaceuticals with real reasoning (valuation, fundamentals, a catalyst or a chart setup). Passing mentions are excluded.